The paths and challenges of “off-the-shelf” CAR-T cell therapy: An overview of clinical trials

The advent of chimeric antigen receptor T cells (CAR-T cells) has made a tremendous revolution in the era of cancer immunotherapy, so that since 2017 eight CAR-T cell products have been granted marketing authorization. All of these approved products are generated from autologous sources, but this st...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2023-12, Vol.169, p.115888-115888, Article 115888
Main Authors: Moradi, Vahid, Omidkhoda, Azadeh, Ahmadbeigi, Naser
Format: Article
Language:English
Subjects:
Allogeneic
CAR (chimeric Antigen Receptor)
Cell- and Tissue-Based Therapy
Clinical
Clinical Trials as Topic
GvHD
Humans
Immunotherapy, Adoptive
Neoplasms - drug therapy
Off-the-shelf
Receptors, Chimeric Antigen
T-Lymphocytes
Trials
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The advent of chimeric antigen receptor T cells (CAR-T cells) has made a tremendous revolution in the era of cancer immunotherapy, so that since 2017 eight CAR-T cell products have been granted marketing authorization. All of these approved products are generated from autologous sources, but this strategy faces several challenges such as time-consuming and expensive manufacturing process and reduced anti-tumor potency of patients’ T cells due to the disease or previous therapies. The use of an allogeneic source can overcome these issues and provide an industrial, scalable, and standardized manufacturing process that reduces costs and provides faster treatment for patients. Nevertheless, for using allogeneic CAR-T cells, we are faced with the challenge of overcoming two formidable impediments: severe life-threatening graft-versus-host-disease (GvHD) caused by allogeneic CAR-T cells, and allorejection of allogeneic CAR-T cells by host immune cells which is called “host versus graft” (HvG). In this study, we reviewed recent registered clinical trials of allogeneic CAR-T cell therapy to analyze different approaches to achieve a safe and efficacious “off-the-shelf” source for chimeric antigen receptor (CAR) based immunotherapy. [Display omitted] •Allogeneic CAR-T cell therapy faces two challenges: GvHD and HvG.•The risk of GvHD can be reduced by blocking TCR expression/signaling.•Elimination of MHC and enhanced lymphodepletion, are approaches to prevent HvG.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2023.115888